Robert Hill1, Thang S Han2, Irina Lubomirova1, Nikhil Math1, Paul Bentley1, Pankaj Sharma3,4. 1. Department of Medicine, Imperial College London, Imperial College Healthcare NHS Trust, London, SW7 2AZ, UK. 2. Institute of Cardiovascular Research, Royal Holloway University of London (ICR2UL), Egham, TW20 0EX, UK. thang.han@rhul.ac.uk. 3. Department of Medicine, Imperial College London, Imperial College Healthcare NHS Trust, London, SW7 2AZ, UK. pankaj.sharma@rhul.ac.uk. 4. Institute of Cardiovascular Research, Royal Holloway University of London (ICR2UL), Egham, TW20 0EX, UK. pankaj.sharma@rhul.ac.uk.
Abstract
BACKGROUND: Urgent reversal of vitamin K antagonists (VKAs) is required for major bleeding or urgent surgery by intravenous vitamin K with either prothrombin complex concentrates (PCCs) or fresh frozen plasma (FFP). However, there is lack of consensus regarding the superiority of either reversal agent. We sought to compare the performance of PCC and FFP in urgent reversal of VKA. METHODS: A meta-analysis was conducted up to November 2018. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random effects model. RESULTS: Seventeen studies comprising 2606 participants met the inclusion criteria. Compared with FFP treatment, PCC treatment led to a reduction in 90-day all-cause mortality (OR 0.60, 95% CI 0.40-0.90, p = 0.01), better reversal of INR (OR 7.36, 95% CI 4.18-12.98; p < 0.00001) and lower risk of at least one treatment-related adverse event (OR 0.45, 95% CI 0.26-0.80, p = 0.006). Among patients with VKA-associated intracranial haemorrhage, PCC treatment led to a reduction in 90-day all-cause mortality (OR 0.58, 95% CI 0.35-0.94, p = 0.03) and better reversal of INR (OR 6.52, 95% CI 1.66-25.59, p = 0.007). There were no differences between these two agents in thrombogenicity, requirement for and quantity of red blood cell transfusions, all adverse events, fluid overload or disability on discharge or at 90 days. CONCLUSIONS: As an agent for urgent reversal of VKA, PCC outperforms FFP in 90-day all-cause mortality including those with VKA-related intracranial haemorrhage, INR reversal and treatment-related adverse events.
BACKGROUND: Urgent reversal of vitamin K antagonists (VKAs) is required for major bleeding or urgent surgery by intravenous vitamin K with either prothrombin complex concentrates (PCCs) or fresh frozen plasma (FFP). However, there is lack of consensus regarding the superiority of either reversal agent. We sought to compare the performance of PCC and FFP in urgent reversal of VKA. METHODS: A meta-analysis was conducted up to November 2018. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random effects model. RESULTS: Seventeen studies comprising 2606 participants met the inclusion criteria. Compared with FFP treatment, PCC treatment led to a reduction in 90-day all-cause mortality (OR 0.60, 95% CI 0.40-0.90, p = 0.01), better reversal of INR (OR 7.36, 95% CI 4.18-12.98; p < 0.00001) and lower risk of at least one treatment-related adverse event (OR 0.45, 95% CI 0.26-0.80, p = 0.006). Among patients with VKA-associated intracranial haemorrhage, PCC treatment led to a reduction in 90-day all-cause mortality (OR 0.58, 95% CI 0.35-0.94, p = 0.03) and better reversal of INR (OR 6.52, 95% CI 1.66-25.59, p = 0.007). There were no differences between these two agents in thrombogenicity, requirement for and quantity of red blood cell transfusions, all adverse events, fluid overload or disability on discharge or at 90 days. CONCLUSIONS: As an agent for urgent reversal of VKA, PCC outperforms FFP in 90-day all-cause mortality including those with VKA-related intracranial haemorrhage, INR reversal and treatment-related adverse events.
Authors: Joshua N Goldstein; Stephen H Thomas; Virginia Frontiero; Annelise Joseph; Chana Engel; Ryan Snider; Eric E Smith; Stephen M Greenberg; Jonathan Rosand Journal: Stroke Date: 2005-11-23 Impact factor: 7.914
Authors: Hagen B Huttner; Peter D Schellinger; Marius Hartmann; Martin Köhrmann; Eric Juettler; Johannes Wikner; Stephan Mueller; Uta Meyding-Lamade; Ralf Strobl; Ulrich Mansmann; Stefan Schwab; Thorsten Steiner Journal: Stroke Date: 2006-05-04 Impact factor: 7.914
Authors: D F O'Shaughnessy; C Atterbury; P Bolton Maggs; M Murphy; D Thomas; S Yates; L M Williamson Journal: Br J Haematol Date: 2004-07 Impact factor: 6.998